BioSpace News Archive

Erasca, Inc. today announced the initiation of the global SEACRAFT-2 Phase 3 trial evaluating the pan-RAF inhibitor naporafenib in combination with the MEK inhibitor trametinib (MEKINIST®) in patients with NRAS-mutant (NRASm) melanoma.

Aethlon Medical, Inc. announced that, on June, 13, 2024, the Human Research Ethics Committee of the Central Adelaide Local Health Network granted full ethics approval for Aethlon’s safety, feasibility and dose-finding clinical trial of the Hemopurifier® in cancer patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Keytruda® or Opdivo® .

Gamida Cell today announced new executive leadership following a successful restructuring transaction (“Transaction”) with certain funds managed by Highbridge Capital Management, LLC (collectively, “Highbridge”) on May 24, 2024.

Newron Pharmaceuticals S.p.A. today announced that it will host its 2024 Investor Day on Tuesday, June 25, 2024, at Convene, 530 Fifth Avenue (between 44th and 45th Streets) in New York City, from 9:00-11:00 AM EDT.

DermTech, Inc., a leader in precision dermatology enabled by a non-invasive skin genomics technology, filed for voluntary chapter 11 protection in the U.S. Bankruptcy Court for the District of Delaware.

Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced that Amit Etkin, M.D., Ph.D., founder and CEO, was named an Entrepreneur Of The Year® 2024 Bay Area Award finalist by EY.

Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, is honored to announce it has been named to Inc. Magazine’s Best Workplaces list.

Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBIO” and the “Company”) today announced that the Company will host a teleconference to update investors and other stakeholders in the Company on a number of business and financial topics.

The Foundation for the National Institutes of Health will award the 2024 Charles A. Sanders, MD, Partnership Award to the National Institutes of Health’s National Institute of Neurological Disorders and Stroke, AbbVie, and Robert and Sarah Newcomb.

Cerevance will deliver a poster presentation at the upcoming Federation of European Neuroscience Societies (FENS) Forum 2024, taking place in Vienna, Austria, from June 25 – 29, 2024.